AstraZeneca and CSPC Pharmaceuticals
Type: License agreement
In-Licensee: AstraZeneca
Out-Licensor: CSPC Pharmaceuticals
Focus: Drug development programs targeting obesity and type 2 diabetes
Upfront Payment: $1.2 billion
Milestone Payment: $3.5 billion
Financial impact: This agreement provides CSPC with significant long-term revenue potential while enabling AstraZeneca to expand its obesity and metabolic disease pipeline globally
AstraZeneca entered a collaboration and licensing agreement with CSPC Pharmaceuticals, paying $1.2 billion upfront and potentially up to $18.5 billion in total including development, regulatory, commercialization, and sales milestones, to gain ex-China rights to CSPC’s long-acting peptide portfolio for obesity and type 2 diabetes, including the once-monthly injectable SYH2082 and three preclinical programs utilizing CSPC’s AI-driven peptide discovery and LiquidGel delivery platforms; the deal, the largest obesity-focused transaction to date, complements AstraZeneca’s growing weight management pipeline built through acquisitions and licensing deals such as SixPeaks Bio and Eccogene, positioning the UK drugmaker to enter the global obesity market.
Six-Year Market Revenue Trend for Obesity Drugs (2020–2025)
The obesity drugs market has shown a steady increase in revenue over the past six years. Obesity is a major contributor to several non-communicable diseases, including heart disease, stroke, and diabetes. The condition arises from multiple interacting factors such as genetics, sociocultural influences, mental health, increased consumption of ultra-processed foods, economic conditions, commercial determinants, and environmental factors. The growing prevalence of obesity reflects the combined impact of these drivers. According to the World Obesity Atlas 2022, the global obese population is expected to reach 16.1% in 2025, representing approximately 892 million people, and is projected to increase further to around 1.025 billion people by 2030, corresponding to a 17.5% prevalence rate.
Six years market revenue of Obesity drugs (2020-2025)
Fig 13: Market revenue of Obesity drugs
Six-Year Market Revenue Trend for Type 2 Diabetes Drugs (2020–2025)
The global Type 2 diabetes drugs market has demonstrated steady growth over the past six years, increasing from approximately USD 51.2 billion in 2020 to around USD 75.1 billion in 2025. This growth is primarily driven by the rising global prevalence of Type 2 diabetes, increasing healthcare expenditure, and the expanding adoption of advanced treatment options. Innovative drug classes such as GLP-1 receptor agonists and SGLT-2 inhibitors have significantly transformed diabetes management by improving glycemic control while also providing cardiovascular and metabolic benefits. These therapies have expanded treatment options for patients and contributed to higher pharmaceutical revenues in the metabolic disease segment.
Six years market revenue of Type 2 Diabetes drugs (2020-2025)
Fig 14: Market revenue of Type 2 Diabetes drugs
The growing burden of diabetes worldwide is a major factor supporting market expansion. Lifestyle changes, ageing populations, and increasing rates of obesity have contributed to a rapid rise in Type 2 diabetes cases globally. As a result, healthcare systems and pharmaceutical companies are investing heavily in the development of innovative therapies to improve disease management and patient outcomes.
Looking ahead, the Type 2 diabetes drugs market is expected to continue expanding, with global revenue projected to reach approximately USD 91.9 billion by 2030, growing at a compound annual growth rate (CAGR) of about 6.9%. This growth will be supported by ongoing drug innovation, increased diagnosis rates, and greater access to treatment in emerging markets.
Eleven years’ market revenue of AstraZeneca
AstraZeneca has demonstrated a steady increase in revenue over the past eleven years, reaching its highest revenue of approximately USD 58.7 billion in 2025, compared with about USD 24.7 billion in 2015. This consistent growth has been driven by strong performance across its oncology, cardiovascular, and rare disease portfolios. Key products contributing to the 2025 revenue include Tagrisso, Farxiga, and Imfinzi, which have generated significant global sales and strengthened the company’s market position. The continued expansion of AstraZeneca’s innovative drug pipeline and strategic collaborations has further supported its long-term revenue growth trajectory.
Eleven years of market revenue of AstraZeneca (2015-2025)
Fig 15: Market revenue of AstraZeneca
Market Impact of This Partnership
The partnership between AstraZeneca and CSPC Pharmaceutical Group is expected to strengthen AstraZeneca’s presence in the rapidly growing obesity and metabolic disease market. Under the agreement, AstraZeneca secured exclusive rights outside China to develop and commercialise CSPC’s long-acting peptide therapies, including the clinical-ready SYH2082, a potential GLP-1/GIP dual agonist for obesity and Type 2 Diabetes. The deal includes an upfront payment of USD 1.2 billion, with potential development and regulatory milestone payments of up to USD 3.5 billion, and additional commercial milestones and royalties that could bring the total value to as much as USD 18.5 billion. Through this collaboration, AstraZeneca gains access to multiple pipeline programs and advanced peptide technologies, positioning the company to compete more effectively in the fast-expanding global obesity drug market.
“AstraZeneca’s USD 18.5 billion partnership with CSPC accelerates its entry into the high-growth obesity and Type 2 diabetes market.”